CA3216743A1 - Gastric residence systems comprising methadone - Google Patents

Gastric residence systems comprising methadone Download PDF

Info

Publication number
CA3216743A1
CA3216743A1 CA3216743A CA3216743A CA3216743A1 CA 3216743 A1 CA3216743 A1 CA 3216743A1 CA 3216743 A CA3216743 A CA 3216743A CA 3216743 A CA3216743 A CA 3216743A CA 3216743 A1 CA3216743 A1 CA 3216743A1
Authority
CA
Canada
Prior art keywords
segment
gastric residence
drug
residence system
arms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3216743A
Other languages
English (en)
French (fr)
Inventor
Estelle BEGUIN
Patricia QUARTON
Jeffrey Katstra
David Altreuter
Juan Jaramillo MONTEZCO
Manjeet PIMPARADE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lyndra Therapeutics Inc
Original Assignee
Lyndra Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lyndra Therapeutics Inc filed Critical Lyndra Therapeutics Inc
Publication of CA3216743A1 publication Critical patent/CA3216743A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
CA3216743A 2021-05-05 2022-05-04 Gastric residence systems comprising methadone Pending CA3216743A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163184760P 2021-05-05 2021-05-05
US63/184,760 2021-05-05
PCT/US2022/072115 WO2022236289A1 (en) 2021-05-05 2022-05-04 Gastric residence systems comprising methadone

Publications (1)

Publication Number Publication Date
CA3216743A1 true CA3216743A1 (en) 2022-11-10

Family

ID=83932453

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3216743A Pending CA3216743A1 (en) 2021-05-05 2022-05-04 Gastric residence systems comprising methadone

Country Status (8)

Country Link
US (1) US20240335400A1 (enExample)
EP (1) EP4333824A4 (enExample)
JP (1) JP2024517829A (enExample)
CN (1) CN117615755A (enExample)
AU (1) AU2022270208A1 (enExample)
CA (1) CA3216743A1 (enExample)
IL (1) IL308211A (enExample)
WO (1) WO2022236289A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020117855A1 (en) 2018-12-03 2020-06-11 Lyndra, Inc. Stomach simulating device
BR112021018496A2 (pt) 2019-03-20 2021-11-30 Lyndra Therapeutics Inc Cápsulas e revestimento de cápsula para formas de dosagem de residência gástrica
AU2020242062B2 (en) 2019-03-20 2025-12-11 Nortiva Bio, Inc. Coatings for gastric residence dosage forms

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011276170B2 (en) * 2010-07-06 2016-03-10 Grunenthal Gmbh Novel gastro- retentive dosage forms comprising a GABA Analog and an opioid
AU2013369379B2 (en) * 2012-12-27 2018-03-15 Hennig Arzneimittel Gmbh & Co. Kg Monolithic dosage form for the modified release of an active ingredient combination
US11576859B2 (en) * 2015-10-23 2023-02-14 Lyndra Therapeutics, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
WO2017100367A1 (en) * 2015-12-08 2017-06-15 Lyndra, Inc. Geometric configurations for gastric residence systems
SG11201901294QA (en) * 2016-09-13 2019-03-28 Alar Pharmaceuticals Inc Sustained-release buprenorphine formulations background of invention
JP2019532947A (ja) * 2016-09-30 2019-11-14 リンドラ，インコーポレイティド アダマンタン系薬物の持続的送達のための胃内滞留システム
CA3066658A1 (en) * 2017-06-09 2018-12-13 Lyndra, Inc. Gastric residence systems with release rate-modulating films

Also Published As

Publication number Publication date
AU2022270208A1 (en) 2023-12-07
EP4333824A1 (en) 2024-03-13
IL308211A (en) 2024-01-01
JP2024517829A (ja) 2024-04-23
EP4333824A4 (en) 2025-04-09
WO2022236289A1 (en) 2022-11-10
CN117615755A (zh) 2024-02-27
US20240335400A1 (en) 2024-10-10

Similar Documents

Publication Publication Date Title
US20240335400A1 (en) Gastric residence systems comprising methadone
AU2017268840B2 (en) Materials architecture for gastric residence systems
US20240390270A1 (en) Gastric residence systems for administration of risperidone
US20220409528A1 (en) Gastric residence systems having a filament for improved gastric residence
CN110996906A (zh) 具有调节释放速度的膜的胃驻留系统
US20240252483A1 (en) Gastric residence systems comprising buprenorphine and naloxone
US20250339368A1 (en) Dosage forms for gastric retention
JP2025531626A (ja) 胃内滞留システムを用いたリスペリドンの投与レジメン
US20240398701A1 (en) Manufacturing methods for gastric residence systems
CN117083059A (zh) 用于利培酮施用的胃滞留系统
TWI837082B (zh) 用於胃滯留系統之材料架構
CN118871091A (zh) 用于胃滞留的剂型
WO2025199123A1 (en) Flexible line configurations for gastric residence systems
TW202500122A (zh) 用於胃滯留系統之材料架構

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250407

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250407